Business
Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights
In the first full quarter since launch, 2,145 healthcare providers prescribed TONMYA®, 3,588 patients initiated treatment, and ~5,400 prescriptions were filled Agreement signed in May with leading group purchasing organization (GPO) that provides access to TONMYA for approximately 35 million U.S. commercial lives Expect to initiate adaptive Phase 2 field study for the prevention of Lyme disease in the U.S. in the first half of 2027 for TNX-4800, pending FDA agreement Approximately $185.5 million
About this update from Tonix Pharmaceuticals Holding Corp.
[{"type":"image","alt":"Tonix Pharmaceuticals Holding Corp.","displaySize":"","headline":null,"caption":"Tonix Pharmaceuticals Holding Corp.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":140,"url":"https://media.zenfs.com/en/globenewswire.com/7794549bf2784a219c2135212e93833d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/EdKFmNH98aOvPDYgJOIgkQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5Ng--/https://media.zenfs.com/en/globenewswire.com/7794549bf2784a219c2135212e93833d","width":300,"height":140},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/EdKFmNH98aOvPDYgJOIgkQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5Ng--/https://media.zenfs.com/en/globenewswire.com/7794549bf2784a219c2135212e93833d","width":300,"height":140}},"lazy":false},{"type":"text","content":"In the first full quarter since launch, 2,145 healthcare providers prescribed TONMYA®, 3,588 patients initiated treatment, and ~5,400 prescriptions were filled","length":159,"tagName":"p"},{"type":"text","content":"Agreement signed in May with leading group purchasing organization (GPO) that provides access to TONMYA for approximately 35 million U.S. commercial lives","length":154,"tagName":"p"},{"type":"text","content":"Expect to initiate adaptive Phase 2 field study for the prevention of Lyme disease in the U.S. in the first half of 2027 for TNX-4800, pending FDA agreement","length":156,"tagName":"p"},{"type":"text","content":"Approximately $185.5 million in cash and cash equivalents as of March 31, 2026","length":78,"tagName":"p"},{"type":"text","content":"BERKELEY HEIGHTS, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced financial results for the quarter ended March 31, 2026, and provided an overview of recent operational highlights.","length":340,"tagName":"p"},{"type":"text","content":"“TONMYA is the first new fibromyalgia medicine in 15 years," said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “TONMYA is a non-opioid analgesic designed for bedtime administration and long-term use by adults. Since launch in November 2025, TONMYA has shown growth in prescriptions, new writers, refills, and patient access. Our first managed care partnership was announced in May, providing ac...